The latest DOR data is expected to support a new drug application, or NDA, for UGN-102 as a treatment for LG-IR-NMIBC, which the company plans to complete in the very near term. There is potential for an FDA decision as early as the first quarter of 2025, assuming the FDA grants priority review. UroGen initiated submission of the rolling NDA for UGN-102 in January.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on URGN:
- Is URGN a Buy, Before Earnings?
- UroGen Pharma Shareholders Shape Governance and Incentives
- UroGen Pharma 5M share Spot Secondary priced at $17.50
- UroGen Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants
- UroGen Pharma announces offering of ordinary shares, warrants